SEC Form 4 · accession 0001562180-18-000299
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Kanes
Officer — Chief Medical Officer
Period of report
Jan 10, 2018
Accepted (ET)
Jan 12, 2018 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 10, 2018 | S | 600 | $170.67 | D | 46,348 | D | |
| Common StockF3 | Jan 10, 2018 | S | 1,200 | $171.80 | D | 45,148 | D | |
| Common StockF4 | Jan 10, 2018 | S | 1,200 | $173.09 | D | 43,948 | D | |
| Common StockF5 | Jan 10, 2018 | S | 2,200 | $174.35 | D | 41,748 | D | |
| Common StockF6 | Jan 10, 2018 | S | 2,461 | $175.03 | D | 39,287 | D | |
| Common StockF7 | Jan 10, 2018 | S | 11,057 | $176.53 | D | 28,230 | D | |
| Common StockF8 | Jan 10, 2018 | S | 9,100 | $177.48 | D | 19,130 | D | |
| Common StockF9 | Jan 10, 2018 | S | 6,923 | $178.33 | D | 12,207 | D | |
| Common StockF10 | Jan 10, 2018 | S | 7,859 | $179.61 | D | 4,348 | D | |
| Common StockF11 | Jan 10, 2018 | S | 1,400 | $180.11 | D | 2,948 | D | |
| Common Stock | Jan 12, 2018 | M | 20,000 | $0.45 | A | 22,948 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F12 | $0.45 | Jan 12, 2018 | M | 20,000 | D | — | Jul 23, 2023 | Common Stock | 20,000 | 111,432 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F10This transaction was executed in multiple trades at prices ranging from $178.99 USD to $179.98 USD. The price reported above reflects the weighted average sale price.
- F11This transaction was executed in multiple trades at prices ranging from $179.99 USD to $180.44 USD. The price reported above reflects the weighted average sale price.
- F12The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on July 18, 2017, subject to continued service through such date.
- F2This transaction was executed in multiple trades at prices ranging from $170.12 USD to $171.02 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $171.41 USD to $172.27 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $172.68 USD to $173.49 USD. The price reported above reflects the weighted average sale price.
- F5This transaction was executed in multiple trades at prices ranging from $173.73 USD to $174.72 USD. The price reported above reflects the weighted average sale price.
- F6This transaction was executed in multiple trades at prices ranging from $174.84 USD to $175.78 USD. The price reported above reflects the weighted average sale price.
- F7This transaction was executed in multiple trades at prices ranging from $175.94 USD to $176.84 USD. The price reported above reflects the weighted average sale price.
- F8This transaction was executed in multiple trades at prices ranging from $176.99 USD to $177.98 USD. The price reported above reflects the weighted average sale price.
- F9This transaction was executed in multiple trades at prices ranging from $177.99 USD to $178.89 USD. The price reported above reflects the weighted average sale price.